Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immuron Limited ( (AU:IMC) ) has issued an update.
Immuron Limited has announced the issuance of 32,909,640 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant provisions. This strategic move reflects Immuron’s adherence to regulatory standards and may influence its market positioning by potentially increasing its capital base.
More about Immuron Limited
Immuron Limited operates in the pharmaceutical industry, focusing on the development and commercialization of oral immunotherapeutic products for the treatment of gut-mediated diseases. The company is listed on both the Australian Securities Exchange (ASX) and NASDAQ.
YTD Price Performance: -3.80%
Average Trading Volume: 138,301
Technical Sentiment Signal: Sell
Current Market Cap: A$17.88M
For detailed information about IMC stock, go to TipRanks’ Stock Analysis page.